Publications by authors named "Laura Codarri Deak"

Claim this Profile
P
PD-1-Cis IL-2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1-IL2v).
Lucy G Hutchinson, Thomas D Lewin, Laura Lauener, Meret Martin-Facklam, Merlind Muecke, Laura Codarri Deak

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity.
Laurène Pousse, Amrita Manchala, Christian Klein, Laura Codarri Deak

MAbs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.
Irene Fusi, Clara Serger, Petra Herzig, Markus Germann, Michael T Sandholzer, Laura Codarri Deak

Sci Transl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment.
Céline Godfroid, Jackeline Romero, Sara Labiano, Chia-Hsien Chuang, Andrea Kelemen, Laura Codarri Deak

J Immunother Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Jacob Gadwa, Maria Amann, Thomas E Bickett, Michael W Knitz, Laurel B Darragh, Laura Codarri Deak

Cell Rep Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Miles Piper, Maureen Hoen, Laurel B Darragh, Michael W Knitz, Diemmy Nguyen, Laura Codarri Deak

Cancer Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.
Laura Codarri Deak, Masao Hashimoto, Pablo Umaña, Christian Klein

Oncoimmunology· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8 T cells and reprogramming macrophages.
Mélanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone, Laura Codarri Deak

Immunity· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Marina Natoli, Klas Hatje, Pratiksha Gulati, Fabian Junker, Petra Herzig, Laura Codarri-Deak

J Immunother Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8 T cells.
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra C Schwalie

Nature· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1.
Fabian Junker, Pratiksha Gulati, Uwe Wessels, Stefan Seeber, Kay-Gunnar Stubenrauch, Laura Codarri-Deak

Cytometry A· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis